David Alan Campbell

CEO · Janux Therapeutics, Inc.

Rank #8,835 SEC EDGAR (United States) ↗ Files from United States

Details

Officer and board memberPharmaceuticals & BiotechnologyJANXSEC CIK 0001864158

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Disclosed holdings
$7.7M
1-day change
▲ 2.22%
Positions on file
1
issuers disclosed in Forms 3/4/5 and Schedules 13D/G

Disclosed holdings over time 53 weekly points

What the 1 currently disclosed position would have been worth at each week’s closing price. A rising line means the shares got more valuable, not that this person bought more.

How the line is built

Share counts are as last reported to the SEC and held constant; only prices move.

2025-09-05$5.0M – $13.0M2026-09-04

Insider activity Sep 27, 2024 – Jan 2, 2026

David Alan Campbell is recorded in filings to the U.S. SEC via EDGAR as officer and board member, and reported 13 transactions between Sep 27, 2024 and Jan 2, 2026. The buy and sell totals below count only codes P, S.

Why the other codes are excluded

Share awards (A), shares withheld to pay tax (F), option exercises (M) and gifts (G) also appear in the table, but they are consequences of a pay package or a private transfer, not a decision to buy or sell on the open market. Counting them would turn this into a compensation ranking.

Open-market buys (code P)
None
0 purchases on file
Open-market sales (code S)
$6.61M
11 sales on file priced rows only
All reported transactions
13
every code, including awards and exercises
Pattern
Net seller in the final 12 months of the window
last 12 months of the window

Events from filings

Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.

David Alan Campbell sold 8,072 Janux Therapeutics, Inc. (JANX) shares for $110,829 on Jan 2, 2026

Unusual change in a direct holding

Flagged because the change that day in the shares this person holds directly was unusually large compared with their own earlier changes. The rows below are the open-market trades reported that day; under each share count is the balance the filing reports after that line.

David Alan Campbell sold 8,072 Janux Therapeutics, Inc. (JANX) shares for $110,829 on Jan 2, 2026
Date Insider Transaction Shares Price Value Filing
Jan 2, 2026 David Alan Campbell S Open-market sale 8,072 held after: 284,982 $13.73 $110,829 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Reported transactions

Price 0.00 is a real reported figure on gifts (G) and share awards (A) — not a missing number. The 15 most recent rows are grouped into 11 lines by date, company and transaction type — open a line to see every lot with its own source link.

How to read this list

Every row is one line of one Form 4 or Form 5, with the filing it came from. Where the record carries no price at all we leave the cell empty instead of guessing one.

The shares and money on a grouped line add up only the lots listed inside that line, and only when every one of them carries the figure. Where a group mixes more than one reporting currency we leave the money blank rather than convert — no source publishes the rate that conversion would need.

  1. Janux Therapeutics, Inc. JANX G Bona fide giftnot a buy/sell decisionreported at zero 123,840 shares $0 at $0.00 SEC filing ↗
  2. Janux Therapeutics, Inc. JANX M Option exercise or conversionnot a buy/sell decision 7,000 shares $29.5K at $4.21 SEC filing ↗
  3. Janux Therapeutics, Inc. JANX S Open-market sale 8,072 shares $110.8K at $13.73 SEC filing ↗
  4. Janux Therapeutics, Inc. JANX A Grant or awardnot a buy/sell decisionreported at zero 96,600 shares $0 at $0.00 SEC filing ↗
  5. Janux Therapeutics, Inc. JANX S Open-market sale 5,000 shares $300.0K at $60.00 SEC filing ↗
  6. Janux Therapeutics, Inc. JANX A Grant or awardnot a buy/sell decisionreported at zero 81,000 shares $0 at $0.00 SEC filing ↗
  7. Janux Therapeutics, Inc. JANX S Open-market sale 25,000 shares $1.40M at $56.19 SEC filing ↗
  8. Janux Therapeutics, Inc. JANX S Open-market sale 15,000 shares $1.01M at $67.00 SEC filing ↗
  9. Janux Therapeutics, Inc. JANX S Open-market sale × 2 25,000 shares $1.29M
    The 2 lots that make up this line, each with the source behind it.
    Shares Price Value Filing
    18,281 $51.43 $940.2K SEC filing ↗
    6,719 $52.04 $349.7K SEC filing ↗
  10. Janux Therapeutics, Inc. JANX S Open-market sale × 2 25,000 shares $1.34M
    The 2 lots that make up this line, each with the source behind it.
    Shares Price Value Filing
    11,103 $53.94 $598.9K SEC filing ↗
    13,897 $53.22 $739.6K SEC filing ↗
  11. Janux Therapeutics, Inc. JANX S Open-market sale × 3 25,000 shares $1.16M
    The 3 lots that make up this line, each with the source behind it.
    Shares Price Value Filing
    795 $47.84 $38.0K SEC filing ↗
    5,248 $46.86 $245.9K SEC filing ↗
    18,957 $46.09 $873.7K SEC filing ↗

Disclosed holdings

Shares is the amount on the form; value is that amount times the closing price shown. Rows with no closing price are left blank, so they may add up to less than the headline figure.

What is not counted here

Each row is one filing you can open. Private companies, real estate, bonds and crypto are not in SEC insider filings and are therefore not counted here.

Equity positions disclosed to the SEC, with the source filing behind each row.
Issuer Ticker Security Shares Close Value Form Reported Filing
Janux Therapeutics, Inc. JANX Common Stock 381,582 $20.24 $7.7M 4 EDGAR ↗

Other insiders at the same companies

People who also file with the SEC at a company where David Alan Campbell reports shares.

Sharing a filing does not mean they work together day to day — it means both names appear on the same issuer’s insider record.

Sources

The filings linked in the tables above are the sources for every figure on this page.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Profile record last refreshed Sep 8, 2026.